This is the authors' abstract. We don't add key points for this paper.
RA hip and knee FLS have distinct transcriptomes, epigenetic marks, and STAT3 activation patterns in the IL-6 pathway. These joint-specific differences might contribute to a differential clinical response in individual joints to targeted therapies such as JAK inhibitors.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hammaker et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: